CN113380342A - 基于mrp2/3的何首乌中肝毒性化合物的快速筛选方法 - Google Patents
基于mrp2/3的何首乌中肝毒性化合物的快速筛选方法 Download PDFInfo
- Publication number
- CN113380342A CN113380342A CN202110654287.XA CN202110654287A CN113380342A CN 113380342 A CN113380342 A CN 113380342A CN 202110654287 A CN202110654287 A CN 202110654287A CN 113380342 A CN113380342 A CN 113380342A
- Authority
- CN
- China
- Prior art keywords
- compound
- docking
- mrp2
- mrp3
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 62
- 241001289529 Fallopia multiflora Species 0.000 title claims abstract description 35
- 231100000334 hepatotoxic Toxicity 0.000 title claims abstract description 26
- 230000003082 hepatotoxic effect Effects 0.000 title claims abstract description 26
- 238000012216 screening Methods 0.000 title claims abstract description 25
- 238000003032 molecular docking Methods 0.000 claims abstract description 107
- 102100028162 ATP-binding cassette sub-family C member 3 Human genes 0.000 claims abstract description 54
- 101000986633 Homo sapiens ATP-binding cassette sub-family C member 3 Proteins 0.000 claims abstract description 48
- 101001122350 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Proteins 0.000 claims abstract description 48
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 210000001503 joint Anatomy 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 13
- 229940125904 compound 1 Drugs 0.000 claims abstract description 11
- 229940125782 compound 2 Drugs 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 101100406343 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mrp-3 gene Proteins 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims abstract description 8
- 238000005516 engineering process Methods 0.000 claims abstract description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 42
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 23
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 12
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 12
- 229960002411 imatinib Drugs 0.000 claims description 12
- 229960000905 indomethacin Drugs 0.000 claims description 12
- 238000005457 optimization Methods 0.000 claims description 6
- 238000007781 pre-processing Methods 0.000 claims description 4
- 238000013332 literature search Methods 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 230000005588 protonation Effects 0.000 claims description 2
- 238000002910 structure generation Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000013537 high throughput screening Methods 0.000 abstract description 2
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 60
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 60
- 231100000304 hepatotoxicity Toxicity 0.000 description 25
- 206010019851 Hepatotoxicity Diseases 0.000 description 24
- 230000007686 hepatotoxicity Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 239000003814 drug Substances 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 150000003384 small molecules Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- UBVJENDWBOVRBS-FHTSYUTFSA-N 1,8-dihydroxy-3-methyl-6-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione Chemical compound C1=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C(O)C=C1O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O UBVJENDWBOVRBS-FHTSYUTFSA-N 0.000 description 6
- ZXXFEBMBNPRRSI-UHFFFAOYSA-N 3'-Prenyl-4'-methoxy-isoflavone-7-O'-??-D-(2''-O-p-coumaroyl)glycopyranoside Natural products C=12C(=O)C3=C(O)C=C(O)C=C3C(=O)C2=CC(C)=CC=1OC1OC(CO)C(O)C(O)C1O ZXXFEBMBNPRRSI-UHFFFAOYSA-N 0.000 description 6
- HSWIRQIYASIOBE-UHFFFAOYSA-N Emodin-8-O-beta-D-glucosid Natural products C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O HSWIRQIYASIOBE-UHFFFAOYSA-N 0.000 description 6
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 6
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 6
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 6
- KIZBWUUJNJEYCM-UHFFFAOYSA-N Aloeemodin-8-monoglucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(CO)C=C1C2=O KIZBWUUJNJEYCM-UHFFFAOYSA-N 0.000 description 5
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 5
- 239000010282 Emodin Substances 0.000 description 5
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 5
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 5
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 5
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 5
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- -1 trans-stilbene glycoside Chemical class 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- WMMOMSNMMDMSRB-JNHRPPPUSA-N chrysophanol 8-O-beta-D-glucoside Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WMMOMSNMMDMSRB-JNHRPPPUSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 238000003041 virtual screening Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- QKPDYSSHOSPOKH-UHFFFAOYSA-N Chrysophanein Natural products C=12C(=O)C3=C(O)C=CC=C3C(=O)C2=CC(C)=CC=1OC1OC(CO)C(O)C(O)C1O QKPDYSSHOSPOKH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 description 3
- 240000001341 Reynoutria japonica Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 3
- 150000004056 anthraquinones Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000005182 potential energy surface Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- OJBWMXFOIJKIJP-UHFFFAOYSA-N 2-acetyl-1,6,8-trihydroxy-3-methylanthracene-9,10-dione Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C(C(=O)C)=C(C)C=C3C(=O)C2=C1 OJBWMXFOIJKIJP-UHFFFAOYSA-N 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- 208000005595 Chronic Idiopathic Jaundice Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 description 2
- 201000004943 Dubin-Johnson syndrome Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- LCOIAYJMPKXARU-VAWYXSNFSA-N salubrinal Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\C1=CC=CC=C1 LCOIAYJMPKXARU-VAWYXSNFSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- ZXXFEBMBNPRRSI-JNHRPPPUSA-N 1,3-dihydroxy-6-methyl-8-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione Chemical compound C=12C(=O)C3=C(O)C=C(O)C=C3C(=O)C2=CC(C)=CC=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZXXFEBMBNPRRSI-JNHRPPPUSA-N 0.000 description 1
- IJTQTRKEXQNUBC-UHFFFAOYSA-N 2-acetylemodin Natural products CC(=O)c1ccc2C(=O)c3cc(O)cc(O)c3C(=O)c2c1O IJTQTRKEXQNUBC-UHFFFAOYSA-N 0.000 description 1
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 1
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 description 1
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
- 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 description 1
- 208000020421 Bilirubin excretion disease Diseases 0.000 description 1
- 108010052500 Calgranulin A Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101001029059 Homo sapiens ATP-binding cassette sub-family C member 10 Proteins 0.000 description 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 1
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 description 1
- 101000986621 Homo sapiens ATP-binding cassette sub-family C member 6 Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000653784 Homo sapiens Protein S100-A12 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100255593 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mrp-9 gene Proteins 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- WLXGUTUUWXVZNM-DQMLXFRHSA-N Physcion 8-glucoside Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WLXGUTUUWXVZNM-DQMLXFRHSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101000986624 Streptococcus pyogenes Fibrinogen- and Ig-binding protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000003003 empirical scoring function Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000002748 hepatotoxicity test Methods 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003095 knowledge based scoring function Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C10/00—Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
Landscapes
- Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Computing Systems (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Databases & Information Systems (AREA)
- Library & Information Science (AREA)
- Bioethics (AREA)
- Software Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
化合物 | 对接打分 |
大黄素-6-O-β-D葡萄糖苷 | 139.643 |
大黄素甲醚-8-β-D-(6′-O-乙酰基)-葡萄糖苷 | 137.405 |
反式二苯乙烯苷 | 126.311 |
大黄酸-8-O-葡萄糖苷 | 124.099 |
虎杖苷 | 123.022 |
大黄酚-8-O-葡萄糖苷 | 118.936 |
大黄素-8-O-β-D-葡萄糖苷 | 118.936 |
大黄素甲醚-8-O-葡萄糖苷 | 117.792 |
大黄酚-8-O-β-D-葡萄糖苷 | 95.2464 |
Emodin 1-O-beta-D-glucoside | 95.1051 |
2-乙酰基大黄素 | 93.7326 |
白藜芦醇 | 72.7515 |
芦荟大黄素-8-O-葡萄糖苷 | 61.0121 |
大黄素 | 53.3076 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110654287.XA CN113380342B (zh) | 2021-06-11 | 2021-06-11 | 基于mrp2/3的何首乌中肝毒性化合物的快速筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110654287.XA CN113380342B (zh) | 2021-06-11 | 2021-06-11 | 基于mrp2/3的何首乌中肝毒性化合物的快速筛选方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113380342A true CN113380342A (zh) | 2021-09-10 |
CN113380342B CN113380342B (zh) | 2023-10-27 |
Family
ID=77573993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110654287.XA Active CN113380342B (zh) | 2021-06-11 | 2021-06-11 | 基于mrp2/3的何首乌中肝毒性化合物的快速筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113380342B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105463061A (zh) * | 2014-09-10 | 2016-04-06 | 中国人民解放军第三〇二医院 | 一种用于评估何首乌特异质肝毒性的方法 |
WO2019016219A1 (fr) * | 2017-07-21 | 2019-01-24 | Plant Advanced Technologies Pat | Extraits racinaires de polygonum multiflorum et leurs utilisations |
CN109464454A (zh) * | 2018-11-29 | 2019-03-15 | 天津中医药大学 | 褐藻寡糖在制备治疗或预防肝损伤的药物中的用途 |
CN112083110A (zh) * | 2019-06-12 | 2020-12-15 | 中国人民解放军总医院第五医学中心 | 一种何首乌导致药物肝损伤标志物的筛选和应用 |
-
2021
- 2021-06-11 CN CN202110654287.XA patent/CN113380342B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105463061A (zh) * | 2014-09-10 | 2016-04-06 | 中国人民解放军第三〇二医院 | 一种用于评估何首乌特异质肝毒性的方法 |
WO2019016219A1 (fr) * | 2017-07-21 | 2019-01-24 | Plant Advanced Technologies Pat | Extraits racinaires de polygonum multiflorum et leurs utilisations |
CN109464454A (zh) * | 2018-11-29 | 2019-03-15 | 天津中医药大学 | 褐藻寡糖在制备治疗或预防肝损伤的药物中的用途 |
CN112083110A (zh) * | 2019-06-12 | 2020-12-15 | 中国人民解放军总医院第五医学中心 | 一种何首乌导致药物肝损伤标志物的筛选和应用 |
Non-Patent Citations (2)
Title |
---|
汪祺 等: "以MRP2/MRP3转运体为作用靶点的何首乌中肝毒性成分筛选", 中国现代中药, vol. 24, no. 04, pages 622 - 628 * |
马宁辉 等: "何首乌相关肝损伤研究进展", 中国中药杂志, vol. 45, no. 15, pages 3594 - 3602 * |
Also Published As
Publication number | Publication date |
---|---|
CN113380342B (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sparreboom et al. | Pharmacogenomics of ABC transporters and its role in cancer chemotherapy | |
KR101977875B1 (ko) | 약물 감응성, 내성, 및 질환 진행성을 예측하기 위한 조성물 및 방법 | |
Sarvagalla et al. | Disruption of protein–protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target–survivin | |
CN104975063A (zh) | 抗肿瘤药物生物标志物的筛选方法及其应用 | |
Musiani et al. | PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy | |
Pallante et al. | In silico investigations of the mode of action of novel colchicine derivatives targeting β-tubulin isotypes: A search for a selective and specific β-III tubulin ligand | |
Dain Md Opo et al. | Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process | |
Li et al. | Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2 | |
Ai et al. | A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors | |
CN113380342B (zh) | 基于mrp2/3的何首乌中肝毒性化合物的快速筛选方法 | |
Zou et al. | Automatic spectroscopic data categorization by clustering analysis (ASCLAN): A data-driven approach for distinguishing discriminatory metabolites for phenotypic subclasses | |
Liang et al. | A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy | |
Huang et al. | Development of simple and accurate in silico ligand-based models for predicting ABCG2 inhibition | |
Halim et al. | Attempt to explore the binding mechanism of IL-1β inhibitors via molecular docking studies | |
CN113380343B (zh) | 基于oatp1b1和oatp1b3的何首乌中肝毒性化合物的快速筛选方法 | |
Tobeigei et al. | Computational high-throughput screening and in vitro approaches identify CB-006-3; A novel PI3K-BRAFV600E dual targeted inhibitor against melanoma | |
Raut et al. | A rational approach to anticancer drug design: 2D and 3D-QSAR, molecular docking and prediction of ADME properties using silico studies of thymidine phosphorylase inhibitors | |
CN113380344B (zh) | 基于fxr的何首乌中肝毒性化合物的快速筛选方法 | |
Xia et al. | Identification of hub genes and therapeutic agents for IgA nephropathy through bioinformatics analysis and experimental validation | |
Wang et al. | Single-cell omics: a new perspective for early detection of pancreatic cancer? | |
Hossain et al. | Systems biology and in silico-based analysis of PCOS revealed the risk of metabolic disorders | |
Satpathy | Application of bioinformatics techniques to screen and characterize the plant-based anti-cancer compounds | |
CN112074485A (zh) | 癌症治疗反应分析 | |
Wang et al. | Effective natural inhibitors targeting LSD1 by computational study | |
Wang et al. | In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm–thumb pocket |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Shuangcheng Inventor after: Wang Qi Inventor after: Wen Hairuo Inventor after: Li Yong Inventor after: Yang Jianbo Inventor after: Yu Jiandong Inventor after: Yao Lingwen Inventor before: Ma Shuangcheng Inventor before: Wang Qi Inventor before: Wen Hairuo Inventor before: Li Yong Inventor before: Yang Jianbo Inventor before: Yu Jiandong Inventor before: Yao Lingwen |
|
GR01 | Patent grant | ||
GR01 | Patent grant |